Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theriva Biologics, Inc. (TOVX) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Theriva’s clinical-stage programs, capital structure, and corporate actions, complementing its press releases and scientific presentations.
Investors can review Form 10-K and Form 10-Q annual and quarterly reports for discussions of risk factors, research and development activities, and financial condition related to programs such as VCN-01, SYN-004 (ribaxamase), SYN-020, and the VCN-X discovery efforts. Current reports on Form 8-K describe material events, including clinical data announcements, regulatory feedback from agencies such as the European Medicines Agency, warrant inducement agreements, public offerings, and at-the-market sales agreements.
Theriva’s proxy statements on Schedule 14A outline matters submitted to stockholders, such as proposals to approve the issuance of additional common shares upon exercise of warrants issued in private placements. These documents explain voting mechanics, record dates, and the rationale for share authorization requests tied to financing transactions.
Forms related to securities offerings, such as registration statements and prospectus supplements referenced in 8-K filings, describe the terms of public offerings of common stock and warrants, as well as at-the-market programs through placement agents. Together, these filings help clarify how Theriva funds the development of its clinical pipeline.
On this page, Stock Titan pairs Theriva’s SEC filings with AI-powered summaries that highlight key points, such as changes in capital structure, new clinical or regulatory disclosures, and important risk factor updates. Real-time updates from EDGAR, along with structured access to historical filings, allow users to monitor how Theriva’s regulatory and financing profile evolves alongside its investigational therapies.
Theriva Biologics (NYSE: TOVX) has announced a significant at-the-market (ATM) offering through an amended sales agreement with A.G.P./Alliance Global Partners. The company plans to offer up to $2.53 million worth of common stock through this facility.
Key details of the ATM offering include:
- Sales will be conducted through A.G.P./Alliance Global Partners as Sales Agent
- Sales Agent commission rate set at 3.0% of gross sales price per share
- Offering falls under the previously effective S-3 Registration Statement (File No. 333-279077) from September 2024
- Sales will be made through methods qualifying as "at the market offering" under Rule 415(a)(4)
The filing includes legal validation through Parsons Behle & Latimer's opinion on share validity. This offering provides Theriva with flexibility to raise capital as needed, though there's no obligation to sell any specific amount of shares.
Theriva Biologics (TOVX) has filed a prospectus supplement for an at-market offering of up to $2,534,352 worth of common stock through A.G.P./Alliance Global Partners. The offering is made under an Amended and Restated At Market Issuance Sales Agreement from February 2021, with subsequent amendments.
Key financial details:
- Previous sales: ~569,000 shares generating net proceeds of ~$3.6M in 2024
- Current stock price: $0.465 (as of June 17, 2025)
- Public float value: ~$12.9M based on 9,049,241 non-affiliate shares
- Sales agent commission: up to 3.0% of gross sales
The company, following its March 2022 acquisition of VCN Biosciences, focuses on developing cancer therapeutics. Their lead candidate, VCN-01, is an oncolytic adenovirus currently in Phase 2b trials for pancreatic cancer and Phase 1 studies for retinoblastoma and other solid tumors. The offering is limited by the one-third public float rule under Form S-3 requirements.